MR1 & B2M Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Nidanilimab | CAN-04 | Phase 2 Clinical | Lund University Foundation | Solid tumours; Biliary Tract Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| CCTx-001 | CCTx-001 | Phase 2 Clinical | Advesya SAS | Leukemia, Myeloid, Acute | Details |
| SAR-445399 | SAR-445399 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| GSK3903371 | GSK3903371 | Clinical | Glaxosmithkline Plc | Neoplasms | Details |